# Clinical trial results:
# A multicenter, randomized, double-blind, placebo-controlled phase 2b dose-finding study to investigate the efficacy and safety of ligelizumab (QGE031) in adolescent patients with Chronic Spontaneous Urticaria (CSU)

## Summary

| | |
|---|---|
| EudraCT number | 2017-004207-52 |
| Trial protocol | DE ES BE HU EE |
| Global end of trial date | 03 February 2021 |

**Results information**

| | |
|---|---|
| Result version number | v1 (current) |
| This version publication date | 13 August 2021 |
| First version publication date | 13 August 2021 |

## Trial information

**Trial identification**

| | |
|---|---|
| Sponsor protocol code | CQGE031C2202 |

**Additional study identifiers**

| | |
|---|---|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT03437278 |
| WHO universal trial number (UTN) | - |

Notes:

**Sponsors**

| | |
|---|---|
| Sponsor organisation name | Novartis Pharma AG |
| Sponsor organisation address | Novartis Campus, Basel, Switzerland, |
| Public contact | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com |
| Scientific contact | Clinical Disclosure Office, Novartis Pharma AG, 41 613241111, Novartis.email@Novartis.com |

Notes:

**Paediatric regulatory details**

| | |
|---|---|
| Is trial part of an agreed paediatric investigation plan (PIP) | No |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

## Results analysis stage

| | |
|---|---|
| Analysis stage | Final |
| Date of interim/final analysis | 03 February 2021 |
| Is this the analysis of the primary completion data? | No |

| | |
|---|---|
| Global end of trial reached? | Yes |
| Global end of trial date | 03 February 2021 |
| Was the trial ended prematurely? | No |

Notes:

## General information about the trial

Main objective of the trial:

Change in the Urticaria Activity Score (UAS7) between baseline and Week 24

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.

Background therapy: -

Evidence for comparator: -

| | |
|---|---|
| Actual start date of recruitment | 01 August 2018 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

## Population of trial subjects

### Subjects enrolled per country

| | |
|---|---|
| Country: Number of subjects enrolled | Argentina: 6 |
| Country: Number of subjects enrolled | Belgium: 1 |
| Country: Number of subjects enrolled | Canada: 4 |
| Country: Number of subjects enrolled | Germany: 13 |
| Country: Number of subjects enrolled | Hungary: 1 |
| Country: Number of subjects enrolled | India: 5 |
| Country: Number of subjects enrolled | Russian Federation: 5 |
| Country: Number of subjects enrolled | Spain: 4 |
| Country: Number of subjects enrolled | Taiwan: 3 |
| Country: Number of subjects enrolled | Turkey: 7 |
| Worldwide total number of subjects | 49 |
| EEA total number of subjects | 19 |

Notes:

### Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |

| | |
|---|---|
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 0 |
| Adolescents (12-17 years) | 49 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

## Subject disposition

### Recruitment

Recruitment details:

Participants were recruited from 20 sites: Argentina (3), Belgium (1), Canada (2), Germany (2), Hungary (1), India (3), Russia (3), Spain (2), Taiwan (1) and Turkey (2).

### Pre-assignment

Screening details:

Participants underwent a Screening period of up to 4 weeks.

### Period 1

| | |
|---|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Carer, Assessor |

### Arms

| | |
|---|---|
| Are arms mutually exclusive? | Yes |
| **Arm title** | Ligelizumab 24 mg |

Arm description:

Participants received a dose of ligelizumab 24 mg (low dose) which consisted of one injection of 0.2 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Ligelizumab |
| Investigational medicinal product code | QGE031 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 24 mg, low dose.

| | |
|---|---|
| **Arm title** | Ligelizumab 120 mg |

Arm description:

Participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive).

| | |
|---|---|
| Arm type | Experimental |
| Investigational medicinal product name | Ligelizumab |
| Investigational medicinal product code | QGE031 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg, high dose.

| | |
|---|---|
| **Arm title** | Placebo + Ligelizumab 120 mg |

Arm description:

Participants received Placebo which consisted of one injection of 1 ml placebo every 4 weeks from Day 1 to Week 8 (inclusive). From week 12 to week 20 (inclusive), participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial.

| | |
|---|---|
| Arm type | Placebo |

| | |
|---|---|
| Investigational medicinal product name | Placebo |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Placebo 0 mg per 1 ml liquid injection once every 4 weeks.

| | |
|---|---|
| Investigational medicinal product name | Ligelizumab |
| Investigational medicinal product code | QGE031 |
| Other name | |
| Pharmaceutical forms | Injection |
| Routes of administration | Intravenous use |

Dosage and administration details:

Ligelizumab comes in 120 mg per 1 ml liquid vials. Participants received one injection every 4 weeks at a dose of 120 mg, high dose.

| **Number of subjects in period 1** | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg |
|---|---|---|---|
| Started | 24 | 13 | 12 |
| Completed | 22 | 13 | 10 |
| Not completed | 2 | 0 | 2 |
| Physician decision | 1 | - | 1 |
| Adverse event, non-fatal | - | - | 1 |
| Progressive disease | 1 | - | - |

## Baseline characteristics

| Reporting groups | |
|---|---|
| Reporting group title | Ligelizumab 24 mg |
| Reporting group description: | |
| Participants received a dose of ligelizumab 24 mg (low dose) which consisted of one injection of 0.2 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive). | |
| Reporting group title | Ligelizumab 120 mg |
| Reporting group description: | |
| Participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive). | |
| Reporting group title | Placebo + Ligelizumab 120 mg |
| Reporting group description: | |
| Participants received Placebo which consisted of one injection of 1 ml placebo every 4 weeks from Day 1 to Week 8 (inclusive). From week 12 to week 20 (inclusive), participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial. | |

| Reporting group values | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg |
|---|---|---|---|
| Number of subjects | 24 | 13 | 12 |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 0 | 0 | 0 |
| Children (2-11 years) | 0 | 0 | 0 |
| Adolescents (12-17 years) | 24 | 13 | 12 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age Continuous<br>Units: Years | | | |
| arithmetic mean | 14.9 | 15.2 | 14.4 |
| standard deviation | ± 1.94 | ± 1.41 | ± 1.51 |
| Sex: Female, Male<br>Units: Participants | | | |
| Female | 10 | 9 | 9 |
| Male | 14 | 4 | 3 |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 7 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 0 |
| White | 16 | 12 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |

| **Reporting group values** | Total | | |
|---|---|---|---|
| Number of subjects | 49 | | |
| Age categorical<br>Units: Subjects | | | |
| In utero | 0 | | |
| Preterm newborn infants (gestational age < 37 wks) | 0 | | |
| Newborns (0-27 days) | 0 | | |
| Infants and toddlers (28 days-23 months) | 0 | | |
| Children (2-11 years) | 0 | | |
| Adolescents (12-17 years) | 49 | | |
| Adults (18-64 years) | 0 | | |
| From 65-84 years | 0 | | |
| 85 years and over | 0 | | |
| Age Continuous<br>Units: Years | | | |
| arithmetic mean | | | |
| standard deviation | - | | |
| Sex: Female, Male<br>Units: Participants | | | |
| Female | 28 | | |
| Male | 21 | | |
| Race (NIH/OMB)<br>Units: Subjects | | | |
| American Indian or Alaska Native | 0 | | |
| Asian | 10 | | |
| Native Hawaiian or Other Pacific Islander | 0 | | |
| Black or African American | 1 | | |
| White | 38 | | |
| More than one race | 0 | | |
| Unknown or Not Reported | 0 | | |

## End points

### End points reporting groups

| | |
|---|---|
| Reporting group title | Ligelizumab 24 mg |
| Reporting group description: | |
| Participants received a dose of ligelizumab 24 mg (low dose) which consisted of one injection of 0.2 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive). | |
| Reporting group title | Ligelizumab 120 mg |
| Reporting group description: | |
| Participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial every 4 weeks from Day 1 to Week 20 (inclusive). | |
| Reporting group title | Placebo + Ligelizumab 120 mg |
| Reporting group description: | |
| Participants received Placebo which consisted of one injection of 1 ml placebo every 4 weeks from Day 1 to Week 8 (inclusive). From week 12 to week 20 (inclusive), participants received a dose of ligelizumab 120 mg (high dose) which consisted of one injection of 1 ml of ligelizumab 120 mg/ 1 ml vial. | |
| Subject analysis set title | All participants with PK data |
| Subject analysis set type | Sub-group analysis |
| Subject analysis set description: | |
| Participants in the study (low dose, high dose and placebo+high dose) with available pharmacokinetic data | |

### Primary: Change from baseline of weekly Urticaria Activity Score (UAS7) at week 24

| | |
|---|---|
| End point title | Change from baseline of weekly Urticaria Activity Score (UAS7) at week 24[1] |
| End point description: | |
| UAS7 is a self-reported scoring system to evaluate urticaria signs and symptoms. UAS7 is the sum of daily urticaria activity scores (UAS) over a seven-day period. The possible range of UAS7 score is 0 to 42 (0 to 6 for daily UAS x 7 days). A higher urticaria activity score indicates more severe symptoms. A negative change score from baseline indicates improvement. Baseline was calculated using data from the 7 days prior to the first treatment date.<br><br>To handle the missing data, if a participant had at least 4 non-missing daily scores within the 7 days prior to a study visit, the weekly score was calculated as the sum of the available scores in that week, divided by the number of days with daily scores available, multiplied by 7. However, if there were less than 4 non-missing daily scores within the prior 7 days, then the weekly score was missing for the week.<br><br>No statistical analysis was planned for this primary outcome. | |
| End point type | Primary |
| End point timeframe: | |
| Baseline, week 24 | |
| Notes: | |
| [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.<br>Justification: Statistical analysis were not planned for this primary endpoint | |

| End point values | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 23 | 13 | 11 | |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | -20.36 (± 12.963) | -22.50 (± 13.503) | -21.26 (± 14.480) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline of weekly Urticaria Activity Score (UAS7) at weeks 12 and 40

| End point title | Change from baseline of weekly Urticaria Activity Score (UAS7) at weeks 12 and 40 |
|---|---|

End point description:

UAS7 is a self-reported scoring system to evaluate urticaria signs and symptoms. UAS7 is the sum of daily urticaria activity scores (UAS) over a seven-day period. The possible range of UAS7 score is 0 to 42 (0 to 6 for daily UAS x 7 days). A higher urticaria activity score indicates more severe symptoms. A negative change score from baseline indicates improvement. Baseline was calculated using data from the 7 days prior to the first treatment date.

To handle the missing data, if a participant had at least 4 non-missing daily scores within the 7 days prior to a study visit, the weekly score was calculated as the sum of the available scores in that week, divided by the number of days with daily scores available, multiplied by 7. However, if there were less than 4 non-missing daily scores within the prior 7 days, then the weekly score was missing for the week.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, weeks 12 and 40

| End point values | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 12 (n=23, 13, 12) | -15.70 (± 10.867) | -18.38 (± 12.268) | -12.96 (± 13.043) | |
| Week 40 (n=22, 12, 10) | -17.50 (± 12.619) | -15.65 (± 11.096) | -19.43 (± 17.667) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants with complete response in weekly Urticaria Activity Score (UAS7)

| End point title | Percentage of participants with complete response in weekly Urticaria Activity Score (UAS7) |
|---|---|

End point description:

UAS7 is a self-reported scoring system to evaluate urticaria signs and symptoms. UAS7 is the sum of daily urticaria activity scores (UAS) over a seven-day period. The possible range of UAS7 score is 0 to 42 (0 to 6 for daily UAS x 7 days). A higher urticaria activity score indicates more severe symptoms. A complete UAS7 response is defined as UAS7=0, no wheals neither pruritus. Participants with post-baseline missing data were considered as non-responders.

| End point type | Secondary |
|---|---|

End point timeframe:

Weeks 12, 24 and 40

| **End point values** | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Participants | | | | |
| Week 12 | 4 | 5 | 2 | |
| Week 24 | 8 | 8 | 4 | |
| Week 40 | 3 | 2 | 4 | |

**Statistical analyses**

No statistical analyses for this end point

## Secondary: Change from baseline of weekly Itch Severity Score (ISS7)

| End point title | Change from baseline of weekly Itch Severity Score (ISS7) |
|---|---|

End point description:

ISS7 is the sum of daily Itch Severity Score (ISS) over a seven-day period. The possible range of ISS7 score is 0-21 (0-3 for daily ISS x 7 days), where 0 is defined as complete ISS7 response (no itching) and 21 is the worst score. A negative change score from baseline indicates improvement. Baseline was calculated using data from the 7 days prior to the first treatment date.

To handle the missing data, if a participant had at least 4 non-missing daily scores within the 7 days prior to a study visit, the weekly score was calculated as the sum of the available scores in that week, divided by the number of days with daily scores available, multiplied by 7. However, if there were less than 4 non-missing daily scores within the prior 7 days, then the weekly score was missing for the week.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, weeks 12, 24 and 40

| **End point values** | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |

| | | | | |
|---|---|---|---|---|
| Week 12 (n=23, 13, 12) | -7.66 (± 5.824) | -7.81 (± 6.047) | -6.34 (± 6.936) | |
| Week 24 (n=23, 13, 12) | -9.71 (± 7.049) | -9.85 (± 6.488) | -10.28 (± 7.811) | |
| Week 40 (n=22, 12, 10) | -8.73 (± 6.656) | -6.86 (± 5.848) | -9.88 (± 8.687) | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants with complete response in weekly Itch Severity Score (ISS7)

| End point title | Percentage of participants with complete response in weekly Itch Severity Score (ISS7) |
|---|---|

End point description:

ISS7 is the sum of daily Itch Severity Score (ISS) over a seven-day period. The possible range of ISS7 score is 0-21 (0-3 for daily ISS x 7 days), where 0 is defined as complete ISS7 response (no itching) and 21 is the worst score. Participants with post-baseline missing data were considered as non-responders.

| End point type | Secondary |
|---|---|

End point timeframe:

Weeks 12, 24 and 40

| End point values | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Participants | | | | |
| Week 12 | 4 | 5 | 2 | |
| Week 24 | 9 | 8 | 4 | |
| Week 40 | 4 | 2 | 4 | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline of weekly Hives Severity Score (HSS7)

| End point title | Change from baseline of weekly Hives Severity Score (HSS7) |
|---|---|

End point description:

HSS7 is the sum of daily Hives Severity Score (HSS) over a seven-day period. The possible range of HSS7 score is 0-21 (0-3 for daily HSS x 7 days), where 0 is defined as complete HSS7 response (no wheals) and 21 is the worst score. A negative change score from baseline indicates improvement. Baseline was calculated using data from the 7 days prior to the first treatment date.

To handle the missing data, if a participant had at least 4 non-missing daily scores within the 7 days prior to a study visit, the weekly score was calculated as the sum of the available scores in that week, divided by the number of days with daily scores available, multiplied by 7. However, if there were less

than 4 non-missing daily scores within the prior 7 days, then the weekly score was missing for the week.

| End point type | Secondary |
|---|---|
| End point timeframe: | |
| Baseline, weeks 12, 24 and 40 | |

| **End point values** | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 12 (n=23, 13, 12) | -8.03 (± 6.307) | -10.58 (± 7.225) | -6.62 (± 6.385) | |
| Week 24 (n=23, 13, 11) | -10.65 (± 6.673) | -12.65 (± 7.785) | -10.98 (± 6.842) | |
| Week 40 (n=22, 12, 10) | -8.77 (± 6.770) | -8.78 (± 6.084) | -9.55 (± 9.197) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Percentage of participants with complete response in weekly Hives Severity Score (HSS7)

| End point title | Percentage of participants with complete response in weekly Hives Severity Score (HSS7) |
|---|---|
| End point description: | |
| HSS7 is the sum of daily Hives Severity Score (HSS) over a seven-day period. The possible range of HSS7 score is 0-21 (0-3 for daily HSS x 7 days), where 0 is defined as complete HSS7 response (no wheals) and 21 is the worst score. Participants with post-baseline missing data were considered as non-responders. | |
| End point type | Secondary |
| End point timeframe: | |
| Weeks 12, 24 and 40 | |

| **End point values** | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Participants | | | | |
| Week 12 | 6 | 6 | 2 | |
| Week 24 | 10 | 9 | 4 | |
| Week 40 | 5 | 2 | 5 | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline of the Children Dermatology Life Quality Index (CDLQI)

| End point title | Change from baseline of the Children Dermatology Life Quality Index (CDLQI) |
|---|---|

End point description:

The children dermatology life quality index questionnaire is a 10-item dermatology- specific health-related quality of life measure designed for use in children. Participants rated their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives. The CDLQI total score is a sum of all 10 item responses, each individual response ranging from 0 (not at all) to 3 (very much). Total score ranges from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative change score from baseline indicates improvement. Baseline was defined as the last non-missing value prior to or on the first treatment date.

To handle the missing data, if a participant had only one item missing score per visit, then it was imputed to 0 and total score was calculated accordingly. If there were 2 or more item missing scores per visit, then the total score for the visit was considered as missing.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, weeks 12, 24 and 40

| **End point values** | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Score on a scale | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 12 (n=19, 13, 11) | -10.1 (± 4.88) | -6.6 (± 8.05) | -5.0 (± 6.23) | |
| Week 24 (n=21, 10, 11) | -11.5 (± 6.85) | -8.8 (± 10.43) | -10.1 (± 6.74) | |
| Week 40 (n=19, 11, 11) | -10.3 (± 6.86) | -5.5 (± 9.04) | -8.6 (± 8.54) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Change from baseline in total human immunoglobulin E (IgE)

| End point title | Change from baseline in total human immunoglobulin E (IgE) |
|---|---|

End point description:

Change from baseline in IgE (free IgE plus IgE bound to ligelizumab) at weeks 12, 24 and 40 as a pharmacodynamic measurement.

| End point type | Secondary |
|---|---|

End point timeframe:

Baseline, weeks 12, 24 and 40

| **End point values** | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: International units / millilitre | | | | |
| arithmetic mean (standard deviation) | | | | |
| Week 12 (n=17, 11, 9) | 186 (± 160) | 245 (± 291) | -43.1 (± 56.2) | |
| Week 24 (n=19, 12, 9) | 169 (± 126) | 328 (± 504) | 325 (± 411) | |
| Week 40 (n=19, 13, 9) | 30.4 (± 105) | -15.6 (± 118) | -22.0 (± 93.0) | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Apparent Clearance (CL/F) of Ligelizumab estimated with PopPK model

| End point title | Apparent Clearance (CL/F) of Ligelizumab estimated with PopPK model |
|---|---|

End point description:

Model-based estimate of apparent clearance (CL/F) was derived using compartmental pharmacokinetic population (PopPK) modelling using non-linear mixed effects model for ligelizumab. Apparent clearance population estimate was derived through fitting individual drug administration history and collected ligelizumab concentrations at the specified data points (listed in Time Frame).

| End point type | Secondary |
|---|---|

End point timeframe:

Weeks 0 (baseline), 4, 8, 12, 16, 20 (all pre-dose) and weeks 24, 32 and 40

| **End point values** | All participants with PK data | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 47 | | | |
| Units: Liters / day | | | | |
| median (inter-quartile range (Q1-Q3)) | 0.66 (0.44 to 1.03) | | | |

## Statistical analyses

No statistical analyses for this end point

## Secondary: Apparent volume of distribution of Ligelizumab estimated with a PopPK model

| End point title | Apparent volume of distribution of Ligelizumab estimated with a PopPK model |
|---|---|

End point description:

Model-based estimate of apparent volume of distribution was derived using compartmental pharmacokinetic population (PopPK) modelling using non-linear mixed effects model for ligelizumab. Apparent volume of distribution population estimate was derived through fitting individual drug administration history and collected ligelizumab concentrations at the specified data points (listed in Time Frame).

| End point type | Secondary |
|---|---|

End point timeframe:

Weeks 0 (baseline), 4, 8, 12, 16, 20 (all pre-dose) and weeks 24, 32 and 40

| End point values | All participants with PK data | | | |
|---|---|---|---|---|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 47 | | | |
| Units: Liters | | | | |
| median (inter-quartile range (Q1-Q3)) | 14.5 (11.02 to 16.65) | | | |

### Statistical analyses

No statistical analyses for this end point

## Secondary: Number of participants with adverse events (AEs) and serious adverse events (SAEs)

| End point title | Number of participants with adverse events (AEs) and serious adverse events (SAEs) |
|---|---|

End point description:

Number of participants with AEs and SAEs, including significant changes from baseline in vital signs (blood pressure, pulse rate), electrocardiograms and laboratory values qualifying and reported as AEs. The number of participants in each category is reported in the table.

| End point type | Secondary |
|---|---|

End point timeframe:

From the start of treatment to 20 weeks after end of treatment, assessed up to maximum duration of 40 weeks

| End point values | Ligelizumab 24 mg | Ligelizumab 120 mg | Placebo + Ligelizumab 120 mg | |
|---|---|---|---|---|
| Subject group type | Reporting group | Reporting group | Reporting group | |
| Number of subjects analysed | 24 | 13 | 12 | |
| Units: Participants | | | | |
| AEs | 18 | 11 | 9 | |
| Treatment related AEs | 6 | 5 | 2 | |

| | | | | |
|---|---|---|---|---|
| SAEs | 1 | 0 | 1 | |
| SAEs leading to treatment discontinuation | 0 | 0 | 1 | |

## Statistical analyses

No statistical analyses for this end point

## Adverse events

| Adverse events information | |
|---|---|
| Timeframe for reporting adverse events: | |
| Adverse events were reported from the start of treatment until 20 weeks after end of treatment, assessed up to maximum duration of 40 weeks | |
| Assessment type | Systematic |

| Dictionary used | |
|---|---|
| Dictionary name | MedDRA |
| Dictionary version | 23.1 |

| Reporting groups | |
|---|---|
| Reporting group title | Ligelizumab 24 mg q4w |
| Reporting group description: | |
| Ligelizumab 24 mg q4w | |
| Reporting group title | Ligelizumab 120 mg q4w |
| Reporting group description: | |
| Ligelizumab 120 mg q4w | |
| Reporting group title | Placebo - Ligelizumab 120 mg q4w |
| Reporting group description: | |
| Placebo - Ligelizumab 120 mg q4w | |
| Reporting group title | Total |
| Reporting group description: | |
| Total | |

| Serious adverse events | Ligelizumab 24 mg q4w | Ligelizumab 120 mg q4w | Placebo - Ligelizumab 120 mg q4w |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 1 / 24 (4.17%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| number of deaths (all causes) | 0 | 0 | 0 |
| number of deaths resulting from adverse events | 0 | 0 | 0 |
| Cardiac disorders | | | |
| Pulmonary valve incompetence | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Tricuspid valve incompetence | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 0 | 1 / 1 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |
| Psychiatric disorders | | | |
| Suicide attempt | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 1 / 24 (4.17%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences causally related to treatment / all | 1 / 1 | 0 / 0 | 0 / 0 |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | 0 / 0 |

| **Serious adverse events** | Total | | |
|---|---|---|---|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| number of deaths (all causes) | 0 | | |
| number of deaths resulting from adverse events | 0 | | |
| Cardiac disorders | | | |
| Pulmonary valve incompetence | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Tricuspid valve incompetence | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |
| Psychiatric disorders | | | |
| Suicide attempt | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences causally related to treatment / all | 1 / 1 | | |
| deaths causally related to treatment / all | 0 / 0 | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| **Non-serious adverse events** | Ligelizumab 24 mg q4w | Ligelizumab 120 mg q4w | Placebo - Ligelizumab 120 mg q4w |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 18 / 24 (75.00%) | 11 / 13 (84.62%) | 9 / 12 (75.00%) |
| Injury, poisoning and procedural complications | | | |
| Animal bite | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Arthropod bite | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Face injury | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 2 | 0 | 1 |
| Headache | | | |
| subjects affected / exposed | 5 / 24 (20.83%) | 1 / 13 (7.69%) | 4 / 12 (33.33%) |
| occurrences (all) | 7 | 2 | 11 |
| Intercostal neuralgia | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Migraine | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 6 | 0 |
| General disorders and administration site conditions | | | |
| Administration site erythema | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Injection site erythema | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Injection site pain | | | |
| subjects affected / exposed | 1 / 24 (4.17%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 1 | 1 |
| Injection site reaction | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Pyrexia | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 2 / 13 (15.38%) | 0 / 12 (0.00%) |
| occurrences (all) | 2 | 2 | 0 |
| Eye disorders | | | |

| | | | |
|---|---|---|---|
| Eye pruritus | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 3 / 24 (12.50%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 9 | 0 | 1 |
| Abdominal pain upper | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Diarrhoea | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 0 / 13 (0.00%) | 2 / 12 (16.67%) |
| occurrences (all) | 2 | 0 | 5 |
| Gastritis | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 2 | 0 | 0 |
| Nausea | | | |
| subjects affected / exposed | 1 / 24 (4.17%) | 3 / 13 (23.08%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 3 | 1 |
| Odynophagia | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Toothache | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Vomiting | | | |
| subjects affected / exposed | 1 / 24 (4.17%) | 3 / 13 (23.08%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 3 | 0 |
| Reproductive system and breast disorders | | | |
| Dysmenorrhoea | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 1 | 2 |
| Menstruation irregular | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Hepatobiliary disorders | | | |

| | | | |
|---|---|---|---|
| Hyperbilirubinaemia | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Respiratory, thoracic and mediastinal disorders | | | |
| Epistaxis | | | |
| subjects affected / exposed | 1 / 24 (4.17%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 3 | 0 | 1 |
| Skin and subcutaneous tissue disorders | | | |
| Angioedema | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 5 | 0 | 1 |
| Chronic spontaneous urticaria | | | |
| subjects affected / exposed | 5 / 24 (20.83%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 10 | 0 | 0 |
| Dry skin | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Onycholysis | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Pruritus | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Urticaria | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 5 | 0 | 0 |
| Back pain | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 0 / 13 (0.00%) | 0 / 12 (0.00%) |
| occurrences (all) | 4 | 0 | 0 |
| Fibromyalgia | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| | | | |
|---|---|---|---|
| Medial tibial stress syndrome | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 1 |
| Muscle spasms | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 0 / 13 (0.00%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 0 | 2 |
| Infections and infestations | | | |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 1 / 12 (8.33%) |
| occurrences (all) | 0 | 1 | 1 |
| Influenza | | | |
| subjects affected / exposed | 2 / 24 (8.33%) | 1 / 13 (7.69%) | 2 / 12 (16.67%) |
| occurrences (all) | 4 | 1 | 2 |
| Nasopharyngitis | | | |
| subjects affected / exposed | 7 / 24 (29.17%) | 4 / 13 (30.77%) | 4 / 12 (33.33%) |
| occurrences (all) | 14 | 9 | 6 |
| Pharyngitis | | | |
| subjects affected / exposed | 1 / 24 (4.17%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 1 | 1 | 0 |
| Post procedural infection | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |
| Rhinitis | | | |
| subjects affected / exposed | 0 / 24 (0.00%) | 2 / 13 (15.38%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 2 | 0 |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 3 / 24 (12.50%) | 2 / 13 (15.38%) | 0 / 12 (0.00%) |
| occurrences (all) | 5 | 3 | 0 |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 24 (4.17%) | 2 / 13 (15.38%) | 1 / 12 (8.33%) |
| occurrences (all) | 1 | 5 | 1 |
| Viral infection | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 0 / 24 (0.00%) | 1 / 13 (7.69%) | 0 / 12 (0.00%) |
| occurrences (all) | 0 | 1 | 0 |

| **Non-serious adverse events** | Total | | |
|---|---|---|---|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 38 / 49 (77.55%) | | |
| Injury, poisoning and procedural complications | | | |
| Animal bite | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Arthropod bite | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| occurrences (all) | 2 | | |
| Face injury | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Nervous system disorders | | | |
| Dizziness | | | |
| subjects affected / exposed | 3 / 49 (6.12%) | | |
| occurrences (all) | 3 | | |
| Headache | | | |
| subjects affected / exposed | 10 / 49 (20.41%) | | |
| occurrences (all) | 20 | | |
| Intercostal neuralgia | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Migraine | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 6 | | |
| General disorders and administration site conditions | | | |
| Administration site erythema | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 2 | | |
| Injection site erythema | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |

| | | | |
|---|---|---|---|
| Injection site pain | | | |
| subjects affected / exposed | 3 / 49 (6.12%) | | |
| occurrences (all) | 3 | | |
| Injection site reaction | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Pyrexia | | | |
| subjects affected / exposed | 4 / 49 (8.16%) | | |
| occurrences (all) | 4 | | |
| Eye disorders | | | |
| Eye pruritus | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Gastrointestinal disorders | | | |
| Abdominal pain | | | |
| subjects affected / exposed | 4 / 49 (8.16%) | | |
| occurrences (all) | 10 | | |
| Abdominal pain upper | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Diarrhoea | | | |
| subjects affected / exposed | 4 / 49 (8.16%) | | |
| occurrences (all) | 7 | | |
| Gastritis | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| occurrences (all) | 2 | | |
| Nausea | | | |
| subjects affected / exposed | 5 / 49 (10.20%) | | |
| occurrences (all) | 5 | | |
| Odynophagia | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Toothache | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Vomiting | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed<br>occurrences (all) | 4 / 49 (8.16%)<br>4 | | |
| Reproductive system and breast disorders<br>Dysmenorrhoea<br>subjects affected / exposed<br>occurrences (all)<br>Menstruation irregular<br>subjects affected / exposed<br>occurrences (all) | <br><br>2 / 49 (4.08%)<br>3<br><br>1 / 49 (2.04%)<br>1 | | |
| Hepatobiliary disorders<br>Hyperbilirubinaemia<br>subjects affected / exposed<br>occurrences (all) | <br><br>1 / 49 (2.04%)<br>1 | | |
| Respiratory, thoracic and mediastinal disorders<br>Epistaxis<br>subjects affected / exposed<br>occurrences (all) | <br><br>2 / 49 (4.08%)<br>4 | | |
| Skin and subcutaneous tissue disorders<br>Angioedema<br>subjects affected / exposed<br>occurrences (all)<br>Chronic spontaneous urticaria<br>subjects affected / exposed<br>occurrences (all)<br>Dry skin<br>subjects affected / exposed<br>occurrences (all)<br>Onycholysis<br>subjects affected / exposed<br>occurrences (all)<br>Pruritus<br>subjects affected / exposed<br>occurrences (all)<br>Urticaria<br>subjects affected / exposed<br>occurrences (all) | <br><br>3 / 49 (6.12%)<br>6<br><br>5 / 49 (10.20%)<br>10<br><br>1 / 49 (2.04%)<br>1<br><br>1 / 49 (2.04%)<br>1<br><br>1 / 49 (2.04%)<br>1<br><br>1 / 49 (2.04%)<br>1 | | |

| | | | |
|---|---|---|---|
| Musculoskeletal and connective tissue disorders | | | |
| Arthralgia | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| occurrences (all) | 5 | | |
| Back pain | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| occurrences (all) | 4 | | |
| Fibromyalgia | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Medial tibial stress syndrome | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Muscle spasms | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 2 | | |
| Infections and infestations | | | |
| Gastrointestinal infection | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| occurrences (all) | 2 | | |
| Influenza | | | |
| subjects affected / exposed | 5 / 49 (10.20%) | | |
| occurrences (all) | 7 | | |
| Nasopharyngitis | | | |
| subjects affected / exposed | 15 / 49 (30.61%) | | |
| occurrences (all) | 29 | | |
| Pharyngitis | | | |
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| occurrences (all) | 2 | | |
| Post procedural infection | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Respiratory tract infection viral | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |
| Rhinitis | | | |

| | | | |
|---|---|---|---|
| subjects affected / exposed | 2 / 49 (4.08%) | | |
| occurrences (all) | 2 | | |
| Upper respiratory tract infection | | | |
| subjects affected / exposed | 5 / 49 (10.20%) | | |
| occurrences (all) | 8 | | |
| Urinary tract infection | | | |
| subjects affected / exposed | 4 / 49 (8.16%) | | |
| occurrences (all) | 7 | | |
| Viral infection | | | |
| subjects affected / exposed | 1 / 49 (2.04%) | | |
| occurrences (all) | 1 | | |

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported